{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:27:45Z","timestamp":1793604465817,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.phrs.2025.108024","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:50:34Z","timestamp":1762275034000},"page":"108024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Protective effect and mechanisms of puerarin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis of animal studies"],"prefix":"10.1016","volume":"222","author":[{"given":"Xiang-yun","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-cheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-ying","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-bin","family":"Zao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong\u2019an","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.phrs.2025.108024_bib1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.phrs.2025.108024_bib2","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.phrs.2025.108024_bib3","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.phrs.2025.108024_bib4","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.phrs.2025.108024_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108024_bib6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3350\/cmh.2024.0109","article-title":"Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"30","author":"Crane","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"issue":"6","key":"10.1016\/j.phrs.2025.108024_bib7","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/eurjpc\/zwab212","article-title":"Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"29","author":"Alon","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2025.108024_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102780","article-title":"The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis","volume":"17","author":"Agustanti","year":"2023","journal-title":"Diabetes Metab. Syndr."},{"issue":"7","key":"10.1016\/j.phrs.2025.108024_bib9","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","article-title":"Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases","volume":"48","author":"Stine","year":"2018","journal-title":"Aliment Pharm. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2025.108024_bib10","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.phrs.2025.108024_bib11","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","article-title":"Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity","volume":"3","author":"Tilg","year":"2021","journal-title":"Nat. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2025.108024_bib12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108024_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr. Rev."},{"issue":"11","key":"10.1016\/j.phrs.2025.108024_bib14","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1111\/dom.15853","article-title":"Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on major liver outcomes in metabolic dysfunction-associated steatotic liver disease","volume":"26","author":"Shen","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2025.108024_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104799","volume":"159","author":"Jalali","year":"2020","journal-title":"Pharm. Res"},{"issue":"10","key":"10.1016\/j.phrs.2025.108024_bib16","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.clnu.2022.08.001","article-title":"Statins' efficacy in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"41","author":"Boutari","year":"2022","journal-title":"Clin. Nutr."},{"issue":"10","key":"10.1016\/j.phrs.2025.108024_bib17","first-page":"Cd015033","article-title":"Vitamin E for people with non-alcoholic fatty liver disease","volume":"10","author":"Wen","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.phrs.2025.108024_bib18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medcli.2021.12.003","article-title":"Bariatric surgery and non-alcoholic fatty liver disease","volume":"158","author":"Juli\u00e0","year":"2022","journal-title":"Med Clin. (Barc. )"},{"issue":"6","key":"10.1016\/j.phrs.2025.108024_bib19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.phrs.2025.108024_bib20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.phrs.2025.108024_bib21","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.phrs.2025.108024_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/fsn3.70101","article-title":"Dietary Phytochemicals in health and disease: mechanisms, clinical evidence, and applications-a comprehensive review","volume":"13","author":"Hossain","year":"2025","journal-title":"Food Sci. Nutr."},{"issue":"12","key":"10.1016\/j.phrs.2025.108024_bib23","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.52586\/5058","article-title":"Puerarin-an isoflavone with beneficial effects on bone health","volume":"26","author":"Kulczy\u0144ski","year":"2021","journal-title":"Front Biosci. (Landmark Ed. )"},{"key":"10.1016\/j.phrs.2025.108024_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117319","article-title":"Protective effects of puerarin on metabolic diseases: Emphasis on the therapeutical effects and the underlying molecular mechanisms","volume":"179","author":"Wan","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.phrs.2025.108024_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.763567","article-title":"A systematic review and meta-analysis on the efficacy of puerarin injection as adjunctive therapy for unstable angina pectoris","volume":"9","author":"Shao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.phrs.2025.108024_bib26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.biopha.2017.05.102","article-title":"Puerarin suppresses LPS-induced breast cancer cell migration, invasion and adhesion by blockage NF-\u03baB and Erk pathway","volume":"92","author":"Liu","year":"2017","journal-title":"Biomed. Pharm."},{"issue":"7","key":"10.1016\/j.phrs.2025.108024_bib27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/ptr.5083","article-title":"Puerarin: a review of pharmacological effects","volume":"28","author":"Zhou","year":"2014","journal-title":"Phytother. Res"},{"issue":"1","key":"10.1016\/j.phrs.2025.108024_bib28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12944-023-01969-y","article-title":"Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation","volume":"22","author":"Yang","year":"2023","journal-title":"Lipids Health Dis."},{"issue":"70, 2019","key":"10.1016\/j.phrs.2025.108024_bib29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1146\/annurev-psych-010418-102803","article-title":"How to do a systematic review: a best practice guide for conducting and reporting narrative reviews, meta-analyses, and meta-syntheses","volume":"70","author":"Siddaway","year":"2019","journal-title":"Annu. Rev. Psychol."},{"issue":"9333","key":"10.1016\/j.phrs.2025.108024_bib30","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0140-6736(02)09812-4","article-title":"Systematic reviews of animal experiments","volume":"360","author":"Sandercock","year":"2002","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.phrs.2025.108024_bib31","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1021\/acs.jafc.3c09601","article-title":"Puerarin induces macrophage M2 polarization to exert antinonalcoholic steatohepatitis pharmacological activity via the activation of autophagy","volume":"72","author":"Fang","year":"2024","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.phrs.2025.108024_bib32","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"issue":"1","key":"10.1016\/j.phrs.2025.108024_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review","volume":"8","author":"Zeng","year":"2015","journal-title":"J. Evid. Based Med"},{"key":"10.1016\/j.phrs.2025.108024_bib34","first-page":"61","article-title":"The effect of puerarin on liver lipids in rats with non-alcoholic fatty liver disease","volume":"01","author":"Zheng","year":"2008","journal-title":"Shanghai J. Tradit. Chin. Med."},{"key":"10.1016\/j.phrs.2025.108024_bib35","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3736\/jcim20080909","article-title":"The effect of puerarin on liver leptin receptor mRNA and phosphorylated Janus kinase 2\/ phosphorylated signal transducer and activator of transcription 3 in rats with non-alcoholic fatty liver disease","volume":"09","author":"Zheng","year":"2008","journal-title":"J. Integr. Tradit. Chin. West. Med."},{"key":"10.1016\/j.phrs.2025.108024_bib36","unstructured":"X. Huo, Study on the Treatment of Non-alcoholic Fatty liver and Atherosclerosis Caused by Experimental Hyperlipidemia in Rabbits with Puerarin, 2008."},{"issue":"3","key":"10.1016\/j.phrs.2025.108024_bib37","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3892\/etm.2013.1461","article-title":"Comparison between the efficacies of curcumin and puerarin in C57BL\/6 mice with steatohepatitis induced by a methionine- and choline-deficient diet","volume":"7","author":"Wang","year":"2014","journal-title":"Exp. Ther. Med"},{"issue":"9","key":"10.1016\/j.phrs.2025.108024_bib38","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/ptr.6417","article-title":"Puerarin protects against high-fat high-sucrose diet-induced non-alcoholic fatty liver disease by modulating PARP-1\/PI3K\/AKT signaling pathway and facilitating mitochondrial homeostasis","volume":"33","author":"Wang","year":"2019","journal-title":"Phytother. Res"},{"issue":"1","key":"10.1016\/j.phrs.2025.108024_bib39","article-title":"The effect of puerarin on fat metabolism in non-alcoholic fatty liver disease","author":"Guo","year":"2019","journal-title":"Diet. Health care"},{"issue":"10","key":"10.1016\/j.phrs.2025.108024_bib40","article-title":"Study on the protective effect of puerarin combined with aerobic exercise on SIRT1-mediated hepatocyte autophagy in rats with non-alcoholic fatty liver disease","volume":"42","author":"Jin","year":"2020","journal-title":"Hebei Tradit. Chin. Med."},{"key":"10.1016\/j.phrs.2025.108024_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.113964","article-title":"Therapeutic potential of puerarin against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis determined by combination of (1)H NMR spectroscopy-based metabonomics and 16S rRNA gene sequencing","volume":"197","author":"Gong","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"02","key":"10.1016\/j.phrs.2025.108024_bib42","first-page":"366","article-title":"Puerarin alleviates non-alcoholic fatty liver injury in rats by inhibiting the I\u03baB\u03b1\/NF-\u03baB p65 signaling axis","volume":"38","author":"Hu","year":"2021","journal-title":"J. Guangzhou Univ. Chin. Med."},{"key":"10.1016\/j.phrs.2025.108024_bib43","unstructured":"G.Q. Liang, The effect of aerobic exercise combined with puerarin on SIRT1-mediated autophagy in rats with fatty liver, 2021."},{"key":"10.1016\/j.phrs.2025.108024_bib44","article-title":"Puerarin ameliorates nonalcoholic fatty liver in rats by regulating hepatic lipid accumulation, oxidative stress, and inflammation","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2025.108024_bib45","article-title":"Puerarin alleviates non-alcoholic steatohepatitis in mice by upregulating the Nrf2 pathway","volume":"31","author":"Zhong","year":"2023","journal-title":"World Chin. Dig. J."},{"issue":"02","key":"10.1016\/j.phrs.2025.108024_bib46","first-page":"239","article-title":"The protective effect of corn peptides on non-alcoholic fatty liver disease in rats induced by high-fat diet","volume":"52","author":"Song","year":"2023","journal-title":"Health Res."},{"key":"10.1016\/j.phrs.2025.108024_bib47","doi-asserted-by":"crossref","first-page":"1423634","DOI":"10.3389\/fphar.2024.1423634","article-title":"Puerarin ameliorates non-alcoholic fatty liver disease by inhibiting lipid metabolism through FMO5","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharm."},{"issue":"03","key":"10.1016\/j.phrs.2025.108024_bib48","first-page":"480","article-title":"Study on the Protective Effect of Puerarin on Non-alcoholic Fatty Liver Disease in Mice","volume":"14","author":"Zhang","year":"2024","journal-title":"Adv. Biotechnol."},{"issue":"04","key":"10.1016\/j.phrs.2025.108024_bib49","first-page":"8","article-title":"Puerarin alleviates liver metabolic disorders in mice with non-alcoholic fatty liver disease","volume":"40","author":"Ding","year":"2024","journal-title":"Mod. Food Technol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108024_bib50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jphs.2025.03.001","article-title":"Puerarin improves MASLD by remodeling intestinal microenvironment to promote mitochondrial fusion and autophagy","volume":"158","author":"Sun","year":"2025","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2025.108024_bib51","first-page":"1056","article-title":"Alcohollike liver disease in nonalcoholics","volume":"95","author":"Diehl","year":"1988","journal-title":"A Clin. Histol. Comp. AlcoholInduc. liver Inj. Gastroenterol."},{"issue":"6","key":"10.1016\/j.phrs.2025.108024_bib52","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.phrs.2025.108024_bib53","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis","volume":"1","author":"Knodell","year":"1981","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/j.phrs.2025.108024_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/nu15183970","article-title":"New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk","volume":"15","author":"Yang","year":"2023","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.phrs.2025.108024_bib55","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"EASL-EASD-EASO","year":"2024","journal-title":"J. Hepatol."},{"issue":"18","key":"10.1016\/j.phrs.2025.108024_bib56","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.phrs.2025.108024_bib57","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108024_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI1411","article-title":"Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1\/SREBP1","volume":"101","author":"Kim","year":"1998","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.phrs.2025.108024_bib59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2011.06.002","article-title":"Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways","volume":"14","author":"Yecies","year":"2011","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.phrs.2025.108024_bib60","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1073\/pnas.0405067102","article-title":"Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c","volume":"102","author":"Hegarty","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"22","key":"10.1016\/j.phrs.2025.108024_bib61","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1101\/gad.844900","article-title":"Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta","volume":"14","author":"Repa","year":"2000","journal-title":"Genes Dev."},{"issue":"4","key":"10.1016\/j.phrs.2025.108024_bib62","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00204-020-02685-7","article-title":"Combinations of LXR and RXR agonists induce triglyceride accumulation in human HepaRG cells in a synergistic manner","volume":"94","author":"Lasch","year":"2020","journal-title":"Arch. Toxicol."},{"issue":"22","key":"10.1016\/j.phrs.2025.108024_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/nu16223876","article-title":"Protective effects of isostrictiniin against high-fat, high-sugar diet-induced steatosis in MASLD mice via regulation of the AMPK\/SREBP-1c\/ACC Pathway","volume":"16","author":"Yan","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.phrs.2025.108024_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155209","article-title":"Si-Ni-San inhibits hepatic Fasn expression and lipid accumulation in MAFLD mice through AMPK\/p300\/SREBP-1c axis","volume":"123","author":"Lan","year":"2024","journal-title":"Phytomedicine"},{"issue":"7","key":"10.1016\/j.phrs.2025.108024_bib65","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1172\/JCI118951","article-title":"Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a","volume":"98","author":"Shimano","year":"1996","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2025.108024_bib66","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.freeradbiomed.2019.06.019","article-title":"Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway","volume":"141","author":"Zhu","year":"2019","journal-title":"Free Radic. Biol. Med"},{"key":"10.1016\/j.phrs.2025.108024_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2021.112029","article-title":"Effects of dibutyl phthalate on lipid metabolism in liver and hepatocytes based on PPAR\u03b1\/SREBP-1c\/FAS\/GPAT\/AMPK signal pathway","volume":"149","author":"Zhang","year":"2021","journal-title":"Food Chem. Toxicol."},{"issue":"6","key":"10.1016\/j.phrs.2025.108024_bib68","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jhep.2014.06.037","article-title":"Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity","volume":"61","author":"Yan","year":"2014","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108024_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010360","article-title":"Antrodan alleviates high-fat and high-fructose diet-induced fatty liver disease in C57BL\/6 Mice Model via AMPK\/Sirt1\/SREBP-1c\/PPAR\u03b3 Pathway","volume":"21","author":"Chyau","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2025.108024_bib70","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cmet.2011.03.009","article-title":"AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice","volume":"13","author":"Li","year":"2011","journal-title":"Cell Metab."},{"issue":"8","key":"10.1016\/j.phrs.2025.108024_bib71","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J. Clin. Invest"},{"issue":"5700","key":"10.1016\/j.phrs.2025.108024_bib72","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1126\/science.1100747","article-title":"Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase","volume":"306","author":"Zimmermann","year":"2004","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.phrs.2025.108024_bib73","doi-asserted-by":"crossref","first-page":"13087","DOI":"10.1074\/jbc.M800533200","article-title":"Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis","volume":"283","author":"Reid","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2025.108024_bib74","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1590\/2359-3997000000067","article-title":"Lipolysis and lipases in white adipose tissue - An update","volume":"59","author":"Bolsoni-Lopes","year":"2015","journal-title":"Arch. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2025.108024_bib75","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/134059","article-title":"PPARs mediate lipid signaling in inflammation and cancer","volume":"2008","author":"Michalik","year":"2008","journal-title":"PPAR Res."},{"issue":"3","key":"10.1016\/j.phrs.2025.108024_bib76","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41419-018-0345-z","article-title":"Hints on ATGL implications in cancer: beyond bioenergetic clues","volume":"9","author":"Vegliante","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2025.108024_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.118165","article-title":"Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways","volume":"329","author":"You","year":"2024","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2025.108024_bib78","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.celrep.2016.03.021","article-title":"Integrated regulation of hepatic lipid and glucose metabolism by adipose triacylglycerol lipase and FoxO proteins","volume":"15","author":"Zhang","year":"2016","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.phrs.2025.108024_bib79","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1194\/jlr.M039867","article-title":"Hepatic ATGL mediates PPAR-\u03b1 signaling and fatty acid channeling through an L-FABP independent mechanism","volume":"55","author":"Ong","year":"2014","journal-title":"J. Lipid Res"},{"issue":"9","key":"10.1016\/j.phrs.2025.108024_bib80","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1002\/ptr.7526","article-title":"Puerarin attenuates hepatic steatosis via G-protein-coupled estrogen receptor-mediated calcium and SIRT1 signaling pathways","volume":"36","author":"Pham","year":"2022","journal-title":"Phytother. Res"},{"issue":"3","key":"10.1016\/j.phrs.2025.108024_bib81","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3892\/ijmm.2015.2074","article-title":"Puerarin ameliorates hepatic steatosis by activating the PPAR\u03b1 and AMPK signaling pathways in hepatocytes","volume":"35","author":"Kang","year":"2015","journal-title":"Int J. Mol. Med"},{"issue":"6","key":"10.1016\/j.phrs.2025.108024_bib82","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1039\/D0FO02761H","article-title":"Puerarin improves hepatic glucose and lipid homeostasis in vitro and in vivo by regulating the AMPK pathway","volume":"12","author":"Xu","year":"2021","journal-title":"Food Funct."},{"issue":"2","key":"10.1016\/j.phrs.2025.108024_bib83","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqz046","article-title":"CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential","volume":"161","author":"Schlaepfer","year":"2020","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.phrs.2025.108024_bib84","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1111\/febs.15877","article-title":"Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease","volume":"289","author":"Thibaut","year":"2022","journal-title":"Febs J."},{"key":"10.1016\/j.phrs.2025.108024_bib85","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.2147\/DDDT.S484531","article-title":"Semaglutide alleviates ovary inflammation via the AMPK\/SIRT1\/NF\u2011\u03baB signaling pathway in polycystic ovary syndrome Mice","volume":"18","author":"Liu","year":"2024","journal-title":"Drug Des. Devel Ther."},{"issue":"1","key":"10.1016\/j.phrs.2025.108024_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010265","article-title":"Cryptotanshinone from the Salvia miltiorrhiza Bunge Attenuates Ethanol-Induced Liver Injury by Activation of AMPK\/SIRT1 and Nrf2 Signaling Pathways","volume":"21","author":"Nagappan","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.108024_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.119890","article-title":"p-Synephrine ameliorates non-alcoholic fatty liver disease by regulating liver-adipose axis via AMPK\/NF-kappa B pathway","volume":"348","author":"Cai","year":"2025","journal-title":"J. Ethnopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108024_bib88","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.yexcr.2017.09.042","article-title":"The crosstalk between Sirt1 and Keap1\/Nrf2\/ARE anti-oxidative pathway forms a positive feedback loop to inhibit FN and TGF-\u03b21 expressions in rat glomerular mesangial cells","volume":"361","author":"Huang","year":"2017","journal-title":"Exp. Cell Res"},{"issue":"2","key":"10.1016\/j.phrs.2025.108024_bib89","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/bbrc.1997.6943","article-title":"An Nrf2\/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements","volume":"236","author":"Itoh","year":"1997","journal-title":"Biochem Biophys. Res Commun."},{"issue":"20","key":"10.1016\/j.phrs.2025.108024_bib90","doi-asserted-by":"crossref","first-page":"11977","DOI":"10.1074\/jbc.270.20.11977","article-title":"Identification of a second region upstream of the mouse heme oxygenase-1 gene that functions as a basal level and inducer-dependent transcription enhancer","volume":"270","author":"Alam","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.phrs.2025.108024_bib91","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1038\/sj.onc.1202237","article-title":"Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes","volume":"17","author":"Venugopal","year":"1998","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.phrs.2025.108024_bib92","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/ars.2012.5149","article-title":"Reactive oxygen species in inflammation and tissue injury","volume":"20","author":"Mittal","year":"2014","journal-title":"Antioxid. Redox Signal"},{"issue":"12","key":"10.1016\/j.phrs.2025.108024_bib93","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1038\/sj.emboj.7600244","article-title":"Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase","volume":"23","author":"Yeung","year":"2004","journal-title":"Embo J."},{"key":"10.1016\/j.phrs.2025.108024_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114508","article-title":"Ethyl caffeate inhibits macrophage polarization via SIRT1\/NF-\u03baB to attenuate traumatic heterotopic ossification in mice","volume":"161","author":"Wang","year":"2023","journal-title":"Biomed. Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2025.108024_bib95","doi-asserted-by":"crossref","first-page":"a001651","DOI":"10.1101\/cshperspect.a001651","article-title":"The nuclear factor NF-kappaB pathway in inflammation","volume":"1","author":"Lawrence","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.phrs.2025.108024_bib96","first-page":"1","article-title":"The improvement effect and mechanism of puerarin on non-alcoholic fatty liver disease induced by high-fat diet in mice","author":"Sitong","year":"2025","journal-title":"Journal Jilin University (Medical Science Edition)"},{"issue":"02","key":"10.1016\/j.phrs.2025.108024_bib97","article-title":"The effect of puerarin on a mouse model of non-alcoholic fatty liver disease based on the liver Dusp9-ASK1 signaling pathway","volume":"39","author":"Shi","year":"2025","journal-title":"J. Pract. Intern. Med. Tradit. Chin. Med."},{"key":"10.1016\/j.phrs.2025.108024_bib98","unstructured":"X.X. Fang, Study on the pharmacological material basis and mechanism of action of Kudzu Root in regulating Autophagy of macrophages and mediating M2 polarization to improve NASH, 2024."},{"key":"10.1016\/j.phrs.2025.108024_bib99","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x2024e13229","article-title":"Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K\/AKT signaling pathway","volume":"57","author":"Yang","year":"2024","journal-title":"Braz. J. Med Biol. Res"},{"key":"10.1016\/j.phrs.2025.108024_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176272","article-title":"Luteolin blocks the ROS\/PI3K\/AKT pathway to inhibit mesothelial-mesenchymal transition and reduce abdominal adhesions","volume":"964","author":"Ren","year":"2024","journal-title":"Eur. J. Pharm."},{"issue":"19","key":"10.1016\/j.phrs.2025.108024_bib101","first-page":"2036","article-title":"The effect and mechanism of puerarin on glycolipid metabolism in mice with non-alcoholic fatty liver disease","volume":"45","author":"Shi","year":"2023","journal-title":"Zhejiang Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.108024_bib102","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1142\/S0192415X09006692","article-title":"Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2\/STAT3 pathways","volume":"37","author":"Zheng","year":"2009","journal-title":"Am. J. Chin. Med"},{"issue":"5","key":"10.1016\/j.phrs.2025.108024_bib103","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1248\/cpb.55.800","article-title":"Studies on preparation and absolute bioavailability of a self-emulsifying system containing puerarin","volume":"55","author":"Quan","year":"2007","journal-title":"Chem. Pharm. Bull. (Tokyo)"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T23:51:43Z","timestamp":1766188303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825004499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":103,"alternative-id":["S1043661825004499"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108024","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective effect and mechanisms of puerarin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis of animal studies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108024"}}